Merck Immunotherapy Drug Shines In Lung Cancer Study

A combination of an immunotherapy drug from Merck and standard chemotherapy led to improved survival for cancer patients.

Research finds that more than two-thirds of lung cancer patients who received Keytruda plus chemotherapy would be alive a year later, compared with about half of people who only got chemotherapy.

(Image credit: Peter Dazeley/Getty Images)